AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aytu BioScience, Inc. (also referred to as Aytu Biopharma, Inc.) on August 10, 2018. The report details a material modification to the rights of security holders regarding the company's capital structure.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance results.
Material Changes
- Reverse Stock Split: The Board of Directors implemented a 1-for-20 reverse stock split of the Company's common stock.
- Effective Date: The split became effective at 4:30 p.m. Eastern Time on August 10, 2018.
- Regulatory Filing: A Certificate of Amendment to the Certificate of Incorporation was filed with the Delaware Secretary of State on August 9, 2018.
- Trading Adjustments: The Common Stock began trading on The Nasdaq Capital Market on a split-adjusted basis on August 13, 2018.
- CUSIP Change: The CUSIP number for the Common Stock was updated to 054754 700.
- Derivative Adjustments: Proportional adjustments were made to outstanding warrants and options to reflect the split.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors beyond the structural change. The primary contingency noted is the adjustment of existing equity instruments (warrants and options) to align with the new share count.
Investor Verification Checklist
- Verify the new CUSIP number (054754 700) for trading purposes.
- Confirm the adjusted share count and price per share following the 1-for-20 split.
- Review the terms of outstanding warrants and options to ensure proportional adjustments were correctly applied.
- Check the trading status on The Nasdaq Capital Market starting August 13, 2018.